Archive for the ‘elsevier’ Category
A genetics researcher included falsified data in two published papers, according to a report by the U.S. Office of Research Integrity (ORI) released today.
At the time of the misconduct, Andrew Cullinane was a postdoctoral fellow in the Medical Genetics Branch at the National Human Genome Research Institute (NHGRI). According to his LinkedIn page, he is now an assistant professor at Howard University in Washington D.C. The university’s College of Medicine lists him as an assistant professor in the Basic Sciences/Anatomy department.
As today’s notice in the Federal Register reports, Cullinane Read the rest of this entry »
With retraction notices continuing to pour in, we like to occasionally take the opportunity to cover several at a time to keep up.
We’ve compiled a handful of retractions that were all issued to papers that were published twice by at least one of the same authors — known as duplication. (Sometimes, this can be the publisher’s fault, although that doesn’t appear to be the case in any of the following examples.)
So here are five recently retracted papers that were pulled because of duplication: Read the rest of this entry »
A journal is retracting a paper by scientists at the U.S. Department of Agriculture about a vaccine to protect fish from a deadly bacterial infection, after an investigation found evidence of data manipulation.
The retraction notice — which appears in the journal Vaccine — cites an investigation by the USDA. It also notes that the authors — who are no longer with the USDA — have not agreed to the retraction.
Last year, we reported on an investigation by the University of Colorado Denver into the research of Rajendra Kadam, which recommended retracting 10 papers. The report also flagged eight additional papers co-authored by Kadam whose data could not be validated, raising “concerns as to the scientific validity and integrity” of the material. A few months later, we reported on some of the notices — four retractions and an EOC — that had begun to appear for Kadam’s manuscripts.
We’ve since discovered more notices, bringing his total to seven retractions and three EOCs.
Kadam was once a prominent member in the lab of Uday Kompella, and often referred to by colleagues as the “golden boy,” according to the institution’s report. In 2012, he won a graduate student symposium award from the American Association of Pharmaceutical Scientists.
A University of Colorado Denver spokesperson told Retraction Watch: Read the rest of this entry »
A pharmacology researcher at Ohio State University has added his seventh retraction, four years after a finding of misconduct by the U.S. Office of Integrity (ORI).
falsified and/or fabricated Western blots in eighteen (18) figures and in six (6) published papers.
In 2012, the ORI finding, which resulted in a three-year funding ban (that is now complete), recommended that Elton retract all six papers, one of which had already been retracted at the time of the report.
Four years later, the last of the six papers flagged by the ORI has finally been retracted by Molecular and Cellular Endocrinology.
A journal has retracted the results of a clinical trial comparing strategies for bladder tumors after the authors mischaracterized the way patients were assigned to each procedure.
In addition, the journal European Urology has pulled a string of correspondence between author Harry Herr at Memorial Sloan Kettering Cancer Center and an outside expert, who had questioned aspects of the study totally unrelated to the methodology, such as its generalizability.
A researcher has pulled a paper about uranium oxide fuel pellets after notifying the journal the data had been falsified — and, what’s more, the publisher can’t verify the identities of the co-authors.
Originally, the Journal of the European Ceramic Society paper suggested a way to increase the compatibility of uranium oxide fuel pellets, which are usually used in nuclear reactors, at high temperatures.
According to the retraction notices issued by Chemosphere, Hong-Wei Luo incorrectly claimed to be affiliated with the Oak Ridge National Laboratory (ORNL) in Tennessee in one of his three affiliations. His other institutions listed on the papers include universities in Singapore and China.
However, an official from the Nanyang Technological University (NTU) in Singapore, told us the work in the now-retracted papers was not carried out at the NTU either.
A tribunal in the UK has rejected an appeal by Queen Mary University of London, who sought to reverse a previous order that they release data from a controversial 2011 paper in The Lancet about chronic fatigue syndrome (CFS).
The decision is one in a long series of judgments about the so-called PACE trial, which reported that two treatments — known as cognitive behavioral therapy and graded exercise therapy — helped alleviate the symptoms of the condition. But ever since The Lancet article and follow-up papers have been published, patients and critics have questioned the conclusions and clamored to see the raw data.
The main criticisms: The findings may prompt some to believe chronic fatigue is a mental, not a physical, disorder, and the PACE program could actually be harmful to patients by encouraging too much exercise. These criticisms were recently bolstered by a re-analysis of the evidence by the Agency for Healthcare Research and Quality, which downgraded its original conclusions about the effectiveness of cognitive behavioral therapy and graded exercise therapy.
In March 2014, Read the rest of this entry »
In 2011, Elsevier announced that it would retract 11 papers by Claudio Airoldi, a researcher at the State University of Campinas (UNICAMP) in Brazil. Subsequently, he was suspended for 45 days, and his co-author on the 11 previously pulled papers, Denis de Jesus Lima Guerra, lost his post at the Federal University of Mato Grosso (also in Brazil).
Now, a 12th retraction has appeared for Airoldi — this time in Thermochimica Acta.